Relationship between 25-（OH）D3 and Disease Activity and Bone Metabolism in Ankylosing Spondylitis
|Keywords||25 - OH D3 Ankylosing Spondylitis Disease activity Bone metabolism|
Objective To evaluate serum 25 - (OH) D3 and disease activity in ankylosing spondylitis (AS), indicators of bone metabolism and bone density, to explore the 25 - (OH) D3 AS immune pathogenic mechanisms. Methods 42 patients with AS and 30 healthy controls included in the study, the two groups in serum 25 - (OH) D3 level, disease activity index (C-reactive protein, erythrocyte sedimentation rate, BASDAI, BASFI, BASMI) were measured and bone metabolism indicators of the (molecular fragments osteocalcin, N-terminal (N-MID) the total I procollagen amino-terminal peptide (tPlNP), collagen type I C-terminal peptide (β-CTx), parathyroid hormone (PTH) and serum calcium ); dual energy X-ray absorptiometry to measure the anteroposterior lumbar spine, femoral neck, Ward's triangle, greater trochanter and total hip bone mineral density (BMD). Compare 25 - (OH) D3, disease activity index, bone metabolic markers and bone mineral density in the difference between the AS group and the healthy control group. AS patients were divided into disease activity group (16 cases) and the inactive group (n = 26), according to the BASDAI score were compared between the two groups of 25 - (OH) D3, bone metabolic markers and bone mineral density differences; based on total hip BMD AS The patients were divided into osteoporosis / reduced bone mass group (n = 19) and normal bone mass group (23 patients), comparing 25 - (OH) D3, disease activity indicators and parameters of bone metabolism in the difference between the two groups; analysis of 25 - (OH) D3 levels and disease activity parameters of bone metabolism, bone mineral density between correlation. Results of patients with AS group of 25 - (OH) D3 levels (15.3 ± 4.9 vs.20.1 ± 4.2, p = 0.012), each part of the hip BMD (p lt; 0.05) significantly lower than the healthy control group, β-CTx level significantly elevated (0.567 ± 0.41 vs.0.363 ± 0.13, p = 0.037). AS disease activity group, 25 - (OH) D3 levels (p = 0.041), lumbar spine BMD (p = 0.022), total hip BMD (p = 0.003) was significantly lower than the the disease inactive group, and β-CTx levels were significantly elevated (p = 0.045). Compared to the normal group of bone mass in patients with AS, 25 - (OH) D3 level decreased in osteoporosis / bone mass group was significantly lower (13.0 ± 3.6 vs.17.1 ± 5.1, p = 0.007), β-CTx (p = 0.016), CRP (p = 0.031), BASDAI (p = 0.002) and BASFI (p = 0.003) were significantly increased. AS patients, 25 - (OH) D3 levels and CRP levels, duration of negative correlation (r = -0.412, p = 0.007; r = -0.329, p = 0.033), with BMD of the lumbar spine, Ward's triangle BMD, greater trochanter BMD e conclusions AS patients, total hip BMD positive correlation (r = 0.452, p = 0.003; r = 0.385, p = 0.012; r = 0.357, p = 0.020; r = 0.393, p = 0.010) 25 - (OH) D3 level decreased significantly, with β-CTx significantly increased and bone density decreased, and related to the disease activity index. Tip 25 - (OH) D3 has a certain role in the pathogenesis and disease monitoring in patients with AS.